Literature DB >> 8384010

Interaction of itraconazole and digoxin.

M K Sachs1, L M Blanchard, P J Green.   

Abstract

A 69-year-old man who had been taking digoxin for 2.5 years developed an elevated serum concentration of digoxin in association with digoxin toxicity (characterized by nausea and vomiting) 9 days after the addition of itraconazole to his regimen for the treatment of sternal osteomyelitis. Coadministration of itraconazole resulted in a statistically significant increase in the half-life of digoxin that necessitated a reduction of the digoxin dose by almost 60%. We thus recommend that patients receiving itraconazole and digoxin concomitantly have serum levels of digoxin monitored frequently. In addition, these patients should be carefully questioned about nonspecific gastrointestinal symptoms, which may indicate early digoxin toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384010     DOI: 10.1093/clind/16.3.400

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions.

Authors:  Kim R Saverno; Lisa E Hines; Terri L Warholak; Amy J Grizzle; Lauren Babits; Courtney Clark; Ann M Taylor; Daniel C Malone
Journal:  J Am Med Inform Assoc       Date:  2010-12-03       Impact factor: 4.497

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Itraconazole-related amaurosis and vomiting due to digoxin toxicity.

Authors:  L A Cone; R B Himelman; J N Hirschberg; J W Hutcheson
Journal:  West J Med       Date:  1996-11

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

6.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 7.  Systemic antifungal agents.

Authors:  W Abuhammour; E Habte-Gabr
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 1.967

Review 8.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 9.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

10.  Voriconazole does not affect the steady-state pharmacokinetics of digoxin.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.